

ASX Announcement

28 September 2023

Cogstate Limited
ABN 80 090 975 723

Level 32
367 Collins Street
Melbourne, Vic, 3000
Australia

P +61 3 9664 1300
F +61 3 9664 1301
W cogstate.com

Investor Presentation by Cogstate Executives

Cogstate (ASX:CGS) advises that senior executives of the company will be hosting a 90-minute investor briefing session on Friday 13 October at 11:00 AM Australian Eastern Summer Time.

DESCRIPTION

Investors are invited to register for a live webcast and Q&A hosted by CEO, Brad O'Connor. The briefing will be focused primarily on Cogstate's Clinical Trials business segment, which represents approximately 90% of Cogstate's current revenue base. Cogstate's clinical trials solutions include not only digital measures of cognition for use as an endpoint or screening tool in clinical trials, but also telehealth-style central rating and quality assurance services for study endpoints that combine innovative operational approaches, advanced analytics and clinical science expertise.

Presenters will include:

- **Rachel Colite, Executive Vice President Clinical Trials.** Rachel will provide an overview of the varied technology and services that Cogstate offers our pharmaceutical company customers.
- **Dr Chris Edgar, Chief Science Officer.** Chris will update investors on the significant recent developments in the field of Alzheimer's disease as well as likely trends that will impact Cogstate's business in coming periods.
- **Dr Pam Ventola, Vice President, Science.** Pam will discuss recent trends in rare disease clinical trials and why these approaches have become strategically important for many biotech companies.

Investors can register via the following weblink to join the live event or receive the recording if unable to attend: <https://bit.ly/cogstate-investor-presentation>

Additionally, a video recording of the presentation will be available following the presentation at the Cogstate Investor Centre homepage: <https://www.cogstate.com/investors/>.

This announcement was authorised for release by Cogstate CEO, Brad O'Connor.

About Cogstate

Cogstate Ltd (ASX:CGS) is a leading neuroscience technology company optimising brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide rapid, reliable and highly sensitive computerised cognitive tests across a growing list of domains and support electronic clinical outcome assessment (eCOA) solutions to replace costly and error-prone paper assessments with real-time data capture. The company's clinical trials solutions include quality assurance services for study endpoints that combine innovative operational approaches, advanced analytics and scientific consulting. For 20 years, Cogstate has proudly supported the leading-edge research needs of biopharmaceutical companies and academic institutions and the clinical care needs of physicians and patients around the world. In the Healthcare market, in August 2019 Cogstate entered into an exclusive licensing agreement with the pharmaceutical company Eisai, under which Eisai will market Cogstate technologies as digital cognitive assessment tools in Japanese markets. In October 2020, Cogstate extended its agreement with Eisai to the Rest of the World. The product, branded as NouKNOW, launched in Japan on 31 March 2020 (nouknow.jp). For more information, please visit www.cogstate.com.

For further information contact:

Brad O'Connor, Chief Executive Officer, boconnor@cogstate.com

Important Notices

Past performance

Past performance is given for illustrative purposes only and should not be relied upon as (and is not) an indication of Cogstate's views on its future financial performance or condition. Past performance of Cogstate cannot be relied upon as an indicator of (and provides no guidance as to) the future performance of Cogstate. Nothing contained in this announcement nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee, whether as to the past, present or future.

Future performance and forward-looking statements

This announcement contains certain "forward-looking statements". The words "expect", "anticipate", "estimate", "intend", "believe", "guidance", "should", "could", "may", "will", "predict", "plan" and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this announcement are based on assumptions and contingencies that are subject to change without notice and involve known and unknown risks and uncertainties and other factors that are beyond the control of Cogstate, its directors and management. Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance.

Actual results, performance or achievements may differ materially from those expressed or implied in such statements and any projections and assumptions on which these statements are based. These statements may assume the success of Cogstate's business strategies, including the that the results of any of those strategies will be realised in the period for which the forward-looking statement may have been prepared or otherwise. For example, Cogstate's performance in any one financial period is sensitive to whether or not contracts are signed in that period, or a subsequent period, and the rate of enrolment in trials of its customers which are influenced by factors that are outside of Cogstate's control.

Readers are cautioned not to place undue reliance on forward-looking statements and except as required by law or regulation, none of Cogstate, its representatives or advisers assumes any obligation to update these forward-looking statements. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this announcement. The forward-looking statements are based on information available to Cogstate as at the date of this announcement. Except as required by law or regulation (including the ASX Listing Rules), none of Cogstate, its representatives or advisers undertakes any obligation to provide any additional or updated information, whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements.